GT BIOPHARMA, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.193 USD | -1.74% |
|
-1.14% | -58.26% |
| Mar. 26 | GT Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Feb. 01 | GT Biopharma to Conduct 1-for-30 Reverse Stock Split; Shares Fall | MT |
GT Biopharma, Inc. specializes in the research and development of therapeutic products used primarily for the treatment of cancer and disorders of the central nervous system.
The group has a portfolio of 3 products in clinical development phase (GTB-3550, GTB-3650 and GTB-5550; treatment of leukemia and solid tumors).
Sector
Pharmaceuticals
Calendar
2024-08-06
- Q2 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
3.193
USD
Average target price
150
USD
Spread / Average Target
+4,597.34%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -58.26% | 4.41M | |
| +31.83% | 588B | |
| -3.42% | 364B | |
| +18.02% | 326B | |
| +4.27% | 285B | |
| +15.26% | 239B | |
| +9.92% | 210B | |
| -7.16% | 200B | |
| +8.12% | 167B | |
| -1.42% | 161B |
- Stock Market
- Equities
- GTBP Stock
- Funds and ETFs GT Biopharma, Inc.